PRO DEX INC - 10-K Summary (Fiscal Year Ended June 30, 2024)
Business Context and Reporting Period
Company: PRO DEX INC (PDEX)
Reporting Period: Fiscal Year Ended June 30, 2024
Business Overview: Pro-Dex specializes in the design, development, and manufacture of autoclavable, battery-powered, and electric multi-function surgical drivers and shavers for orthopedic, thoracic, and craniomaxillofacial (CMF) markets. The company also manufactures rotary air motors. Operations are conducted through a single segment with facilities in Irvine and Tustin, California.
Key Financial Metrics
| Metric (in thousands) | Fiscal 2024 | Fiscal 2023 |
|---|---|---|
| Net Sales | $53,844 | $46,087 |
| Gross Profit | $14,551 | $12,749 |
| Gross Margin | 27% | 28% |
| Operating Income | $7,173 | $5,762 |
| Net Income | $2,127 | $7,074 |
| Diluted EPS | $0.60 | $1.95 |
| Operating Cash Flow | $6,199 | $5,462 |
| Working Capital | $23,719 | $21,303 |
| Cash & Equivalents | $2,631 | $2,936 |
| Total Debt (Notes Payable) | $11,910 | $12,738 |
Note: Total Debt includes current and non-current notes payable. Fiscal 2024 Net Income was significantly impacted by a $4.1 million unrealized loss on marketable equity investments.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 17% ($7.8 million) driven by a 31% increase in repair revenue ($3.9 million) and a 20% increase in medical device sales ($6.2 million). This was partially offset by a 71% decline in NRE and prototype services.
- Profitability Decline: Net income decreased 70% year-over-year. While operating income grew 24%, the bottom line was reduced by a $4.1 million unrealized loss on investments compared to a $3.9 million unrealized gain in the prior year.
- Customer Concentration: Concentration increased. The top customer accounted for 71% of sales in 2024 (up from 67% in 2023). The top three customers accounted for 88% of total sales.
- Backlog: Order backlog decreased significantly to $19.8 million from $41.6 million, attributed to the timing of customer orders rather than a reduction in demand.
- Share Repurchases: The company repurchased 184,901 shares for $3.5 million in fiscal 2024, compared to 86,422 shares for $1.5 million in fiscal 2023.
Guidance, Outlook, and Risks
Outlook: Management does not expect a reduction in fiscal 2025 revenue compared to fiscal 2024. The company anticipates continued demand for "enhanced repairs" of orthopedic handpieces. The new Tustin facility is fully operational, providing capacity for future growth.
Material Weaknesses in Internal Controls: The company identified material weaknesses in internal control over financial reporting as of June 30, 2024, specifically related to inventory accounting and the valuation of Level 2 investments. Remediation plans are underway.
Key Risks:
- Customer Dependence: Loss of the largest customer (71% of sales) would have a material adverse effect.
- Investment Volatility: Significant exposure to marketable equity securities ($5.8 million fair value) creates volatility in net income due to unrealized gains/losses.
- Debt Covenants: Debt agreements restrict dividends, additional debt, and asset sales. Compliance with financial ratios is required.
- Supply Chain: Suppliers have increased lead times and prices; reliance on single-source suppliers for high-value components exists.
Investor Verification Checklist
- Investment Valuation: Verify the methodology and assumptions used for the $5.8 million investment portfolio, particularly the $3.2 million stake in Monogram Technologies and the $4.1 million unrealized loss impact.
- Customer Retention: Confirm the status of the supply agreement with the largest customer (71% of revenue), which runs through calendar 2025.
- Internal Control Remediation: Monitor progress on remediation plans for inventory counting and investment valuation controls to ensure future financial statement reliability.
- Backlog Conversion: Assess the ability to convert the reduced backlog ($19.8M) into revenue for fiscal 2025 given the timing of customer orders.
- Debt Maturity: Review the scheduled principal maturities, noting $4.4 million due in fiscal 2025, and the company's ability to service this debt from operating cash flows.